HRP20241557T1 - Proteini koji vezuju receptor aktivina tipa 2 i njihova uporaba - Google Patents

Proteini koji vezuju receptor aktivina tipa 2 i njihova uporaba Download PDF

Info

Publication number
HRP20241557T1
HRP20241557T1 HRP20241557TT HRP20241557T HRP20241557T1 HR P20241557 T1 HRP20241557 T1 HR P20241557T1 HR P20241557T T HRP20241557T T HR P20241557TT HR P20241557 T HRP20241557 T HR P20241557T HR P20241557 T1 HRP20241557 T1 HR P20241557T1
Authority
HR
Croatia
Prior art keywords
actrii
antibody
constant domain
disease
human
Prior art date
Application number
HRP20241557TT
Other languages
English (en)
Croatian (hr)
Inventor
Ravindra Kumar
Jonathan Belk
Asya Grinberg
Dianne Sako
Roselyne CASTONGUAY
Original Assignee
Acceleron Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc. filed Critical Acceleron Pharma Inc.
Publication of HRP20241557T1 publication Critical patent/HRP20241557T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
HRP20241557TT 2016-03-10 2017-03-10 Proteini koji vezuju receptor aktivina tipa 2 i njihova uporaba HRP20241557T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662306354P 2016-03-10 2016-03-10
EP17764253.5A EP3426680B1 (en) 2016-03-10 2017-03-10 Activin type 2 receptor binding proteins and uses thereof
PCT/US2017/021958 WO2017156488A2 (en) 2016-03-10 2017-03-10 Activin type 2 receptor binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
HRP20241557T1 true HRP20241557T1 (hr) 2025-05-23

Family

ID=59790844

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20241557TT HRP20241557T1 (hr) 2016-03-10 2017-03-10 Proteini koji vezuju receptor aktivina tipa 2 i njihova uporaba

Country Status (19)

Country Link
US (4) US10307455B2 (https=)
EP (2) EP3426680B1 (https=)
JP (4) JP6987072B2 (https=)
KR (4) KR102866147B1 (https=)
CN (2) CN116284392A (https=)
AU (1) AU2017230091B2 (https=)
BR (1) BR112018067813A2 (https=)
CA (1) CA3015277A1 (https=)
DK (1) DK3426680T3 (https=)
ES (1) ES2987504T3 (https=)
FI (1) FI3426680T3 (https=)
HR (1) HRP20241557T1 (https=)
HU (1) HUE069467T2 (https=)
LT (1) LT3426680T (https=)
PL (1) PL3426680T3 (https=)
PT (1) PT3426680T (https=)
RS (1) RS66251B1 (https=)
SI (1) SI3426680T1 (https=)
WO (1) WO2017156488A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116284392A (zh) 2016-03-10 2023-06-23 艾科赛扬制药股份有限公司 活化素2型受体结合蛋白及其用途
JP7669291B2 (ja) * 2019-05-30 2025-04-28 アクセレロン ファーマ インコーポレーテッド Ａｃｔｒｉｉ結合性タンパク質及びその使用
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
US20230174620A1 (en) * 2020-04-28 2023-06-08 Acceleron Pharma Inc. Actrii proteins and use in treating post-capillary pulmonary hypertension
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
EP4252782A4 (en) * 2020-11-30 2025-12-10 Cspc Megalith Biopharmaceutical Co Ltd ANTI-CLDN18.2 ANTIBODY, DRUG CONJUGATE, RELATED PREPARATION METHOD AND ASSOCIATED USE
MX2023014761A (es) * 2021-06-11 2024-01-19 Acceleron Pharma Inc Proteínas actrii y usos de las mismas.
JP2025529933A (ja) 2022-08-26 2025-09-09 バーサニス・バイオ・インコーポレイテッド ＡｃｔＲＩＩ抗体固定単位用量の治療
WO2025027052A1 (en) 2023-07-31 2025-02-06 Sixpeaks Bio Ag Antibody conjugates and fusion proteins

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE229046T1 (de) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
WO1997021728A1 (en) * 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
JP2000515003A (ja) 1996-05-20 2000-11-14 ノボ ノルディスク アクティーゼルスカブ タンパク質加水分解物を得る方法
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
RU2221809C2 (ru) 1997-10-03 2004-01-20 Тугаи Сейяку Кабусики Кайся Способ получения природного гуманизированного антитела
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
WO2001002588A2 (en) 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
ZA200503075B (en) 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
RU2322261C2 (ru) 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
EP1740609A2 (en) 2004-04-27 2007-01-10 Research Development Foundation Antagonism of tgf-beta superfamily receptor signaling
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
AU2005272646A1 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
CA2581208A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
CA2538208A1 (en) 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
EP1929305A2 (en) 2005-08-31 2008-06-11 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2007067616A2 (en) 2005-12-06 2007-06-14 Amgen Inc Uses of myostatin antagonists
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
WO2007109668A2 (en) 2006-03-20 2007-09-27 The Uab Research Foundation Compositions and methods for improving bone mass through modulation of novel receptors of pth and fragments thereof
EP2052088A2 (en) 2006-08-02 2009-04-29 Genizon Biosciences Genemap of the human genes associated with psoriasis
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EA018221B1 (ru) * 2007-02-09 2013-06-28 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
EP2238154B1 (en) 2008-01-18 2015-09-16 Bio-Rad Laboratories, Inc. Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
JP5611222B2 (ja) 2008-11-26 2014-10-22 アムジエン・インコーポレーテツド アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
PE20120532A1 (es) 2009-04-27 2012-05-18 Novartis Ag ANTICUERPOS ANTI-ActRIIB
ITAN20090010U1 (it) 2009-04-27 2010-10-28 Arnaldo Sorci Staffa di bloccaggio protettiva
EP3202459B1 (en) 2009-09-09 2021-04-14 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
EP2497168A1 (en) 2009-11-05 2012-09-12 The Regents of the University of California Semipolar {20-21} iii-nitride laser diodes with etched mirrors
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
EP2595657A4 (en) * 2010-07-22 2015-09-23 Univ California ANTI-TUMOR ANTIGEN ANTIBODIES AND USE PROCESSES
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
TW201249867A (en) * 2011-04-01 2012-12-16 Astellas Pharma Inc Novel anti-human il-23 receptor antibody
JP6472999B2 (ja) * 2011-07-01 2019-02-20 ノバルティス アーゲー 代謝障害を治療するための方法
BR112014000392A2 (pt) * 2011-07-14 2017-02-21 Pfizer tratamento com anticorpos anti-pcsk9
US8765385B2 (en) * 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
WO2013063536A1 (en) * 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
HK1203384A1 (en) 2011-12-19 2015-12-11 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US9029510B2 (en) 2012-03-30 2015-05-12 Sorrento Therapeutics, Inc. Fully human antibodies that bind to VEGFR2 and methods of use thereof
NZ703724A (en) * 2012-06-11 2017-06-30 Amgen Inc Dual receptor antagonistic antigen-binding proteins and uses thereof
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
JP6049767B2 (ja) 2013-02-01 2016-12-21 株式会社ブリリアントサービス 栽培システム、栽培プログラム、および栽培方法
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
WO2014172448A2 (en) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
HK1221908A1 (zh) 2013-04-29 2017-06-16 Adimab, Llc 多特异(polyspecificity)试剂，其制备方法和用途
HK1219280A1 (zh) 2013-08-14 2017-03-31 Novartis Ag 治疗偶发性包涵体肌炎之方法
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
TN2017000217A1 (en) 2014-12-08 2018-10-19 Novartis Ag Myostatin or activin antagonists for the treatment of sarcopenia
CN116284392A (zh) 2016-03-10 2023-06-23 艾科赛扬制药股份有限公司 活化素2型受体结合蛋白及其用途
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
KR102866147B1 (ko) 2025-09-30
RS66251B1 (sr) 2024-12-31
EP3426680A4 (en) 2020-03-11
HUE069467T2 (hu) 2025-03-28
ES2987504T3 (es) 2024-11-15
JP7469284B2 (ja) 2024-04-16
KR20180128421A (ko) 2018-12-03
US10307455B2 (en) 2019-06-04
SI3426680T1 (sl) 2025-07-31
KR20250142947A (ko) 2025-09-30
FI3426680T3 (fi) 2024-11-13
PL3426680T3 (pl) 2025-03-31
DK3426680T3 (da) 2024-09-16
WO2017156488A2 (en) 2017-09-14
US20190365844A1 (en) 2019-12-05
US20240374671A1 (en) 2024-11-14
JP2019513015A (ja) 2019-05-23
EP4465045A3 (en) 2025-02-26
JP6987072B2 (ja) 2021-12-22
WO2017156488A3 (en) 2017-11-09
AU2017230091B2 (en) 2022-04-07
AU2017230091A1 (en) 2018-08-30
CN109153713B (zh) 2022-12-27
EP4465045A2 (en) 2024-11-20
KR20230152153A (ko) 2023-11-02
US20170281711A1 (en) 2017-10-05
PT3426680T (pt) 2024-10-02
JP2026004489A (ja) 2026-01-14
JP2022058340A (ja) 2022-04-12
JP2024026159A (ja) 2024-02-28
CN116284392A (zh) 2023-06-23
LT3426680T (lt) 2025-01-27
JP7755634B2 (ja) 2025-10-16
EP3426680A2 (en) 2019-01-16
CN109153713A (zh) 2019-01-04
EP3426680B1 (en) 2024-08-14
KR102457751B1 (ko) 2022-10-21
US12042524B2 (en) 2024-07-23
CA3015277A1 (en) 2017-09-14
KR102592109B1 (ko) 2023-10-23
BR112018067813A2 (pt) 2019-01-15
KR20220147704A (ko) 2022-11-03
US11000565B2 (en) 2021-05-11
US20210308206A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
HRP20241557T1 (hr) Proteini koji vezuju receptor aktivina tipa 2 i njihova uporaba
JP2020508655A5 (https=)
JP2019524693A5 (https=)
RU2018142544A (ru) Биспецифические связывающие белки и пути их применения
HRP20231134T1 (hr) Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu
WO2010100200A2 (en) Lyophilised antibody formulation
JP2020514277A5 (https=)
JP2019520797A5 (https=)
JP2018522888A5 (https=)
JP2019513018A5 (https=)
JP2013523184A5 (https=)
JP2018509175A5 (https=)
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2015521466A5 (https=)
HRP20220405T1 (hr) Protutijela protiv ngf i njihova upotreba
JP2018503380A5 (https=)
JP2010526028A5 (https=)
IL270554B1 (en) Method of preparing ph-dependent antibodies
JP2018502840A5 (https=)
SI2424895T1 (en) Ingredients and procedures for increasing muscle growth
JP2017533694A5 (https=)
HRP20240415T1 (hr) Kimerni antigenski receptori antigena kapa mijeloma i njihova upotreba
JP2024026159A5 (https=)
JP2021520825A5 (https=)
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)